All In Biotech

Drug Trial Radar · NCT07217860

An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)

A Multicenter, Long-term, Open-Label, Safety, Tolerability, and Efficacy Study of Azetukalner in Bipolar I or II Depression

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Jun 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Xenon Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Oct 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar depression study.

Conditions

  • Bipolar Depression
  • Bipolar I Disorder
  • Bipolar Disorder
  • Bipolar II Disorder

Interventions

  • AzetukalnerDrug

    Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severity and frequency of treatment-emergent adverse events, serious adverse events, adverse events of special interest, and events of clinical interestTime frame: From the start of treatment in the open-label extension study through 8 weeks after the last dose

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Woodland International Research Group

    Little Rock, Arkansas

  • Woodland Research Northwest

    Rogers, Arkansas

  • Clinical Innovations, Inc, dba CITrials

    Bellflower, California

  • ProScience Research Group

    Culver City, California

  • Clinical Innovations, Inc

    Riverside, California

  • PharmaSouth Research, LLC

    Coral Gables, Florida

  • Clinical Neuroscience Solutions, LLC

    Jacksonville, Florida

  • Central Miami Medical Institute

    Miami, Florida

  • Clinical Neuroscience Solutions, LLC

    Orlando, Florida

  • Synexus Clinical Research, Inc.

    Atlanta, Georgia

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • CenExel iResearch

    Decatur, Georgia

  • Denali Health Atlanta, LLC

    Stone Mountain, Georgia

  • Advanced Quality Medical Research

    Orland Park, Illinois

  • Lumina Clinical Research Center

    Cherry Hill, New Jersey

  • Neurobehavioral Research Inc

    Cedarhurst, New York

  • Lehigh Center for Clinical Research

    Allentown, Pennsylvania

  • Clinical Neuroscience Solutions, LLC

    Memphis, Tennessee

  • Grayline Research Center

    Wichita Falls, Texas

  • Core Clinical Research

    Everett, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.